These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 8101146

  • 21. Evaluation of somatostatin receptors in human cancer.
    Pantev T, Virgolini I, Neuhold N, Angelberger P, Luger A, Sinzinger H.
    Wien Klin Wochenschr; 1991; 103(21):649-53. PubMed ID: 1663300
    [Abstract] [Full Text] [Related]

  • 22. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
    Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R.
    Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
    [Abstract] [Full Text] [Related]

  • 23. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
    Janson ET, Westlin JE, Eriksson B, Ahlström H, Nilsson S, Oberg K.
    Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
    [Abstract] [Full Text] [Related]

  • 24. SPECT imaging with 111In-octreotide for the localization of pancreatic insulinoma.
    Signore A, Procaccini E, Chianelli M, Salerno G, Iozzo P, Annovazzi A, Leonetti F, Tamburrano G, Ronga G.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):111-2. PubMed ID: 9002765
    [Abstract] [Full Text] [Related]

  • 25. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.
    Kwekkeboom DJ, Krenning EP.
    Eur Radiol; 1997 Dec; 7(7):1103-9. PubMed ID: 9265684
    [Abstract] [Full Text] [Related]

  • 26. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW.
    Life Sci; 1991 Dec; 49(22):1583-91. PubMed ID: 1658515
    [Abstract] [Full Text] [Related]

  • 27. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A.
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [Abstract] [Full Text] [Related]

  • 28. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt M, Béhé M, Mäcke HR, Krenning EP.
    Int J Cancer; 1998 Jan 30; 75(3):406-11. PubMed ID: 9455802
    [Abstract] [Full Text] [Related]

  • 29. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
    Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, Schipper ML, Kalinowski M, Arnold R, Oyen WJ, Behr TM.
    Endocr Relat Cancer; 2006 Dec 30; 13(4):1203-11. PubMed ID: 17158765
    [Abstract] [Full Text] [Related]

  • 30. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec 30; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 31. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.
    Semin Nucl Med; 2002 Apr 30; 32(2):133-40. PubMed ID: 11965608
    [Abstract] [Full Text] [Related]

  • 32. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver.
    Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH.
    Int J Cancer; 1999 May 31; 81(5):767-71. PubMed ID: 10328231
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours.
    Castaldi P, Rufini V, Treglia G, Bruno I, Perotti G, Stifano G, Barbaro B, Giordano A.
    Radiol Med; 2008 Oct 31; 113(7):1056-67. PubMed ID: 18797822
    [Abstract] [Full Text] [Related]

  • 35. Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide.
    Breeman WA, Hofland LJ, Bakker WH, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Kwekkeboom DJ, Visser TJ, Lamberts SW.
    Eur J Nucl Med; 1993 Nov 31; 20(11):1089-94. PubMed ID: 7904561
    [Abstract] [Full Text] [Related]

  • 36. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA, Papadogias D, Makras P, Grossman AB.
    Endocr Relat Cancer; 2005 Dec 31; 12(4):683-99. PubMed ID: 16322317
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
    de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Béhé M, Powell P, Mäcke HR.
    Eur J Nucl Med; 1997 Apr 31; 24(4):368-71. PubMed ID: 9096086
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
    Kaltsas GA, Mukherjee JJ, Grossman AB.
    Ann Oncol; 2001 Apr 31; 12 Suppl 2():S47-50. PubMed ID: 11762352
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.